ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

ClinicalTrials.gov ID: NCT03563248

Public ClinicalTrials.gov record NCT03563248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 30, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Study identification

NCT ID
NCT03563248
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Massachusetts General Hospital
Other
Enrollment
168 participants

Conditions and interventions

Interventions

  • FOLFIRINOX Drug
  • Losartan Drug
  • Nivolumab Drug
  • SBRT Radiation
  • Surgery Procedure

Drug · Radiation · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 9, 2018
Primary completion
Feb 15, 2022
Completion
Mar 31, 2027
Last update posted
Sep 30, 2025

2018 – 2027

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
University of Colorado Cancer Center Aurora Colorado 80045
Sibley Memorial Hospital Washington D.C. District of Columbia 20016
The Johns Hopkins Hospital Baltimore Maryland 21287
Massachusetts General Hospital Boston Massachusetts 02114
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Brigham and Women's Hospital Boston Massachusetts 02215
Dana Farber Cancer Institute Boston Massachusetts 02215
Newton Wellesley Hospital Newton Massachusetts 02462
New York University Langone Medical Center New York New York 10016
MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03563248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 30, 2025 · Synced Apr 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03563248 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →